NEW YORK (GenomeWeb) – Biocept said today that it has signed an in-network provider agreement for its Target Selector liquid biopsy platform with Wellmark Blue Cross Blue Shield in Iowa and South Dakota.

This is Biocept's third BCBS contract and enables cancer patients to access the company's testing services in network under their Wellmark health plans.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.